Welcome to Central Library, SUST

MHC Class I Antigens In Malignant Cells (Record no. 44660)

MARC details
000 -LEADER
fixed length control field 03680nam a22005177a 4500
001 - CONTROL NUMBER
control field sulb-eb0022568
003 - CONTROL NUMBER IDENTIFIER
control field BD-SySUS
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20160413122306.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130228s2013 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781461465430
-- 978-1-4614-6543-0
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-4614-6543-0
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Aptsiauri, Natalia.
Relator term author.
245 10 - TITLE STATEMENT
Title MHC Class I Antigens In Malignant Cells
Medium [electronic resource] :
Remainder of title Immune Escape And Response To Immunotherapy /
Statement of responsibility, etc. by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York, NY :
Name of producer, publisher, distributor, manufacturer Springer New York :
-- Imprint: Springer,
Date of production, publication, distribution, manufacture, or copyright notice 2013.
300 ## - PHYSICAL DESCRIPTION
Extent VIII, 51 p. 17 illus., 14 illus. in color.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
490 1# - SERIES STATEMENT
Series statement SpringerBriefs in Cancer Research ;
Volume/sequential designation 6
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
520 ## - SUMMARY, ETC.
Summary, etc. Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  .
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
Topical term or geographic name as entry element Cancer research.
Topical term or geographic name as entry element Immunology.
Topical term or geographic name as entry element Molecular biology.
Topical term or geographic name as entry element Biomedicine.
Topical term or geographic name as entry element Cancer Research.
Topical term or geographic name as entry element Immunology.
Topical term or geographic name as entry element Molecular Medicine.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Garcia-Lora, Angel Miguel.
Relator term author.
Personal name Cabrera, Teresa.
Relator term author.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9781461465423
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title SpringerBriefs in Cancer Research ;
Volume number/sequential designation 6
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1007/978-1-4614-6543-0">http://dx.doi.org/10.1007/978-1-4614-6543-0</a>
912 ## -
-- ZDB-2-SBL
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Koha item type

No items available.